Codex DNA Showcases Next Generation Automated Synthetic Biology Workstation at World of Technology & Science in Utrecht, Netherlands
September 26 2022 - 7:00AM
Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop
synthetic biology systems, will showcase its recently released
BioXp™ 9600 system at the World of Technology & Science
conference which begins tomorrow in Utrecht, Netherlands. The
BioXp™ 9600 system will be showcased at the Codex DNA booth in
Hall 7 number A091.
The BioXp™ 9600 system, a next-generation high throughput
platform that builds biology overnight and at the push of a button
empowering scientists to accelerate discovery of new vaccines and
biologics, is the third release on the powerful and versatile
BioXp™ platform.
The fully automated BioXp™ system enables scientists to overcome
process limitations created by the turnaround time, cost, or
complexity of alternative means of building or acquiring DNA and
mRNA. The BioXp™ system provides over-night, automated synthesis of
genes, clones, DNA libraries, and mRNA, enabling users to more
tightly integrate design and build cycles, driving greater
productivity and reducing time to answer.
The BioXp™ 9600 system expands on the capability of the
award-winning BioXp™ platform, offering greater throughput,
performance, and versatility in workflow capability. The
state-of-the art automation design combined with proprietary Gibson
Assembly and error correction methods enable turnkey synthesis,
assembly and cloning of up to 96 unique sequences in a single
overnight run. With innovative high-throughput sample processing,
this system boosts throughput, turnaround time and productivity
while maintaining a benchtop footprint, so researchers can
eliminate synthesis bottlenecks, retain control of their
high-throughput discovery workflows, and advance seamlessly from
design to testing in a matter of days.
About Codex DNACodex DNA is empowering
scientists with the ability to create novel, synthetic
biology-enabled solutions for many of humanity’s greatest
challenges. As inventors of the industry-standard Gibson Assembly®
method and the first commercial automated benchtop DNA and mRNA
synthesis system, Codex DNA is enabling rapid, accurate, and
reproducible writing of DNA and mRNA for numerous downstream
markets. The award-winning BioXp™ system consolidates, automates,
and optimizes the entire synthesis, cloning, and amplification
workflow. As a result, it delivers virtually error-free synthesis
of DNA and RNA at scale within days and hours instead of weeks or
months. Scientists around the world are using the technology in
their own laboratories to accelerate the design-build-test paradigm
for novel, high-value products for precision medicine, biologics
drug discovery, vaccine and therapeutic development, genome
editing, and cell and gene therapy. Codex DNA is a public company
based in San Diego. For more information,
visit codexdna.com.
Codex DNA, the Codex DNA logo, Gibson Assembly, BioXp, and
RapidAMP are trademarks of Codex DNA Inc.
Forward-Looking StatementsThis press release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended. Such
forward-looking statements are based on Codex DNA’s beliefs and
assumptions and on information currently available to it on the
date of this press release. Forward-looking statements may involve
known and unknown risks, uncertainties and other factors that may
cause Codex DNA’s actual results, performance, or achievements to
be materially different from those expressed or implied by the
forward-looking statements. These and other risks are described
more fully in Codex DNA’s filings with the Securities and Exchange
Commission (“SEC”) and other documents that Codex DNA subsequently
files with the SEC from time to time. Except to the extent required
by law, Codex DNA undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Media Contact:Charlie SchmidtSr. Director of
Marketingcharlie@codexdna.com
Codex DNA (NASDAQ:DNAY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Codex DNA (NASDAQ:DNAY)
Historical Stock Chart
From Sep 2023 to Sep 2024